<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001830371</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001805387</issuerCik>
      <issuerName>Cerevel Therapeutics Holdings, Inc.</issuerName>
      <secFileNumber>001-39311</secFileNumber>
      <issuerAddress>
        <com:street1>222 JACOBS STREET</com:street1>
        <com:street2>SUITE 200</com:street2>
        <com:city>CAMBRIDGE</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02141</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>844-304-2048</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Bodenrader Mark</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Officer</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>ETRADE FINANCIAL CORPORATION</name>
        <address>
          <com:street1>3 EDISON DRIVE</com:street1>
          <com:city>ALPHARETTA</com:city>
          <com:stateOrCountry>GA</com:stateOrCountry>
          <com:zipCode>30005</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>1895</noOfUnitsSold>
      <aggregateMarketValue>62440.25</aggregateMarketValue>
      <noOfUnitsOutstanding>156832992</noOfUnitsOutstanding>
      <approxSaleDate>06/02/2023</approxSaleDate>
      <securitiesExchangeName>Nasdaq</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>06/01/2023</acquiredDate>
      <natureOfAcquisitionTransaction>RSU Vesting</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>4733</amountOfSecuritiesAcquired>
      <paymentDate>06/01/2023</paymentDate>
      <natureOfPayment>Compensation</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <noticeSignature>
      <noticeDate>06/05/2023</noticeDate>
      <signature>/s/ Mark Bodenrader</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
[{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 2776}]
144
0001830371
XXXXXXXX
LIVE
0001805387
Cerevel Therapeutics Holdings, Inc.
001-39311
222 JACOBS STREET
SUITE 200
CAMBRIDGE
MA
02141
844-304-2048
Bodenrader Mark
Officer
Common Stock
ETRADE FINANCIAL CORPORATION
3 EDISON DRIVE
ALPHARETTA
GA
30005
1895
62440.25
156832992
06/02/2023
Nasdaq
Common Stock
06/01/2023
RSU Vesting
Issuer
N
4733
06/01/2023
Compensation
Y
06/05/2023
/s/ Mark Bodenrader